Compare TYRA & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TYRA | WD |
|---|---|---|
| Founded | 2018 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2021 | 2010 |
| Metric | TYRA | WD |
|---|---|---|
| Price | $22.30 | $41.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | $47.45 | ★ $49.33 |
| AVG Volume (30 Days) | ★ 563.7K | 529.6K |
| Earning Date | 11-20-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 6.96% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,234,306,000.00 |
| Revenue This Year | N/A | $7.05 |
| Revenue Next Year | N/A | $9.53 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.99 |
| 52 Week Low | $13.83 | $31.40 |
| 52 Week High | $40.65 | $69.19 |
| Indicator | TYRA | WD |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 69.46 |
| Support Level | $18.46 | $39.01 |
| Resistance Level | $22.37 | $43.13 |
| Average True Range (ATR) | 1.04 | 1.64 |
| MACD | 0.27 | 0.98 |
| Stochastic Oscillator | 76.27 | 96.91 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.